{
    "id": "0535",
    "question": "Please refer to the summary above to answer this question\nA medical student is examining the table in the abstract. She notices that the standard error surrounding measurements in the pulmharkimab 150 mg/day group is generally greater than the standard errors for the placebo and pulmharkimab 75 mg/day groups. Which of the following statements is the best explanation for the increased standard error in the pulmharkimab 150 mg/day group?\"\n\"Impact of pulmharkimab on asthma control and cardiovascular disease progression in patients with coronary artery disease and comorbid asthma\nIntroduction:\nActive asthma has been found to be associated with a more than two-fold increase in the risk of myocardial infarction, even after adjusting for cardiovascular risk factors. It has been suggested that the inflammatory mediators and accelerated atherosclerosis characterizing systemic inflammation may increase the risk of both asthma and cardiovascular disease. This study evaluated the efficacy of the novel IL-1 inhibitor pulmharkimab in improving asthma and cardiovascular disease progression.\nMethods:\nIn this double-blind, randomized controlled trial, patients (N=1200) with a history of coronary artery disease, myocardial infarction in the past 2 years, and a diagnosis of comorbid adult-onset asthma were recruited from cardiology clinics at a large academic medical center in Philadelphia, PA. Patients who were immunocompromised or had a history of recurrent infections were excluded.\nPatients were subsequently randomly assigned a 12-month course of pulmharkimab 75 mg/day, pulmharkimab 150 mg/day, or a placebo, with each group containing 400 participants. All participants were included in analysis and analyzed in the groups to which they were randomized regardless of medication adherence. Variables measured included plaque volume, serum LDL-C levels, FEV1/FVC ratio, and Asthma Control Questionnaire (ACQ) scores, which quantified the severity of asthma symptoms. Plaque volume was determined by ultrasound.\nAnalyses were performed from baseline to month 12.\nResults:\nAt baseline, participants in the two groups did not differ by age, gender, race, plaque volume, serum LDL-C levels, FEV1/FVC ratio, and ACQ scores (p > 0.05 for all). A total of 215 participants (18%) were lost to follow-up. At 12-month follow-up, the groups contained the following numbers of participants:\nPulmharkimab 75 mg/d: 388 participants\nPulmharkimab 150 mg/d: 202 participants\nPlacebo: 395 participants\nTable 1: Association between pulmharkimab and both pulmonary and cardiovascular outcomes. Models were adjusted for sociodemographic variables and medical comorbidities. All outcome variables were approximately normally distributed.\nPulmharkimab 75 mg/d, (Mean +/- 2 SE) Pulmharkimab 150 mg/d, (Mean +/- 2 SE) Placebo, (Mean +/- 2 SE) P-value\nPlaque volume (mm3), change from baseline 6.6 \u00b1 2.8 1.2 \u00b1 4.7 15.8 \u00b1 2.9 < 0.01\nLDL-C levels, change from baseline -9.4 \u00b1 3.6 -11.2 \u00b1 14.3 -8.4 \u00b1 3.9 0.28\nFEV1/FVC ratio, change from baseline 0.29 \u00b1 2.21 0.34 \u00b1 5.54 -0.22 \u00b1 3.21 0.27\nACQ scores, change from baseline 0.31 \u00b1 1.22 0.46 \u00b1 3.25 0.12 \u00b1 1.33 0.43\nConclusion:\nPulmharkimab may be effective in reducing plaque volume but does not lead to improved asthma control in patients with a history of myocardial infarction and comorbid asthma.\nSource of funding: Southeast Institute for Advanced Lung and Cardiovascular Studies, American Center for Advancement of Cardiovascular Health\"",
    "options": {
        "A": "It indicates decreased external validity",
        "B": "It indicates a lack of statistical significance",
        "C": "It reflects a smaller sample size",
        "D": "It indicates more narrow confidence intervals"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To determine the best explanation for the increased standard error in the pulmharkimab 150 mg/day group, we need to analyze the data provided in the table. The standard error (SE) is a measure of the variability of the sample mean, and a larger SE indicates less precise estimates. In this case, the SE for the pulmharkimab 150 mg/day group is greater than the SE for the placebo and pulmharkimab 75 mg/day groups. This suggests that the estimates of the effect of pulmharkimab on the outcomes are less precise for the 150 mg/day group compared to the other two groups. The standard error is influenced by several factors, including sample size, variability in the data, and the number of participants in each group. However, the sample sizes for the three groups are similar (400 participants per group), so we can rule out a smaller sample size as the primary cause of the increased standard error. Option B, a lack of statistical significance, is not directly related to the standard error. Statistical significance is determined by the p-value, which is not provided in the table. Option D, a narrower confidence interval, is the opposite of what we observe. A narrower confidence interval would indicate more precise estimates, which is not the case for the pulmharkimab 150 mg/day group. Therefore, the most plausible explanation for the increased standard error in the pulmharkimab 150 mg/day group is option A, a decreased external validity. However, this option is not directly related to the standard error. A more likely explanation would be that the increased standard error is due to the increased variability in the data for the 150 mg/day group. However, this is not explicitly stated in the options. Given the options provided, the best answer is A, but it is not a perfect explanation. The correct answer should be that the increased standard error is due to the increased variability in the data, but this option is not available. Therefore, we have to choose the best available option from the provided choices. Given the options provided, the best answer is A, but with the understanding that it is not the most accurate explanation.\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 12.983671426773071
}